Abstract:Background: We aimed to develop and validate a radiomics signature based on pretreatment MRI images to predict a good response (GR) to neoadjuvant chemotherapy (nCRT) in patients with locally advanced rectal cancer (LARC) and to research its prognostic value in predicting distant metastasis.Methods: A total of 922 patients with LARC were retrospectively recruited from 3 Chinese hospitals between Dec 1, 2009, and Jan 30, 2018. The training dataset was comprised of 509 patients from centre I; external validation dataset 1 (EVD1) was comprised of 242 patients from centre II; and EVD2 was comprised of 171 patients from centre III. The radiomics features were extracted from the T2WI and ADC images. A three-step procedure, including the least absolute shrinkage and selection operator (LASSO) algorithm, minority oversampling technique (SMOTE) and support vector machine (SVM) classifier, was applied for feature selection and signature building. The prediction performance was evaluated using the area under the curve (AUC), accuracy, sensitivity and specificity. A nomogram integrating the radiomics signature and clinical-MRI features to predict distant metastasis (DM) was constructed.Findings: Nineteen, 3, and 22 radiomic features were selected in the T2WI-based, ADC-based, and fusion models for GR prediction, respectively. Among the three models, the fusion model showed satisfactory discrimination of GR to nCRT and yielded AUCs of 0.89±0.02 (95% CI, 0.87−0.92), 0.69±0.05 (95% CI, 0.61−0.78), and 0.72±0.04 (95% CI, 0.65−0.79) in the training and two external validation datasets, respectively. In addition, the combined nomogram was successfully built with AUCs of 0.69, 0.78 and 0.66 in the three datasets. Kaplan‒Meier curves of disease-free survival(DFS) between the high-risk and low-risk DM patients who were grouped by the nomogram showed statisticalsignificance with p<0.05 in the three datasets.Interpretation:The MRI-based radiomics signature exhibited promising performance for response prediction to nCRT in LARC patients and can also provide prognostic value for DM prediction, which may assist in individualized clinical treatment.Funding Information: This study was supported by the National Natural Science Foundation of China (No. 82001776, 81971687, 82271946), Shanghai AntiCancer Association Young Eagle Program (SACA-CY20C130),Shanghai Natural Science Foundation (No. 20ZR1412700). Declaration of Interests: All authors declare no competing interests. Ethics Approval Statement: This retrospective multicentre study was conducted in accordance with the Declaration of Helsinki. Ethics approval was obtained from the Institutional Review Board of all participating centres, and the requirement for informed consent was waived due to the retrospective nature. A total of 509 consecutive patients with LARC were enrolled in Fudan University Shanghai Cancer Center (FUSCC) from 2016/05 to 2018/01; 171 consecutive patients from 2013/03 to 2016/11 were enrolled in Shanxi Cancer Hospital (SXPCH); and 242 consecutive patients from 2009/12 to 2015/05 were enrolled in Beijing Cancer Hospital (BJCH).

An inflammation index-based prediction of treatment response to neoadjuvant chemoradiotherapy for rectal mucinous adenocarcinoma

Predictive value of circulating lymphocyte subsets and inflammatory indexes for neoadjuvant chemoradiotherapy response in rectal mucinous adenocarcinoma patients: A machine learning approach

Radiomics Model Based on Intratumoral and Peritumoral Features for Predicting Major Pathological Response in Non-Small Cell Lung Cancer Receiving Neoadjuvant Immunochemotherapy

An Immune-Related Gene Signature for Predicting Neoadjuvant Chemoradiotherapy Efficacy in Rectal Carcinoma

Predicting Treatment Response to Neoadjuvant Chemoradiotherapy in Rectal Mucinous Adenocarcinoma Using an MRI-Based Radiomics Nomogram

Predictors and Risk Factors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Population-Based Analysis

Radiomics Signature Based on Support Vector Machines for the Prediction of Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

Radiomics for the Prediction of Pathological Complete Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Prospective Observational Trial.

Value of Pretreatment Inflammation-nutrition Score to Predict Non-response to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer.

Predictive Value of Inflammatory Indicators on the Efficacy of Preoperative Neoadjuvant Chemotherapy in Patients With Locally Advanced Rectal Cancer

Mucinous histology is a negative predictor of neoadjuvant chemoradiotherapy for locally advanced rectal adenocarcinoma

Prognostic impact of preoperative immunonutritional status in rectal mucinous adenocarcinoma

Predicting the response to neoadjuvant chemoradiation for rectal cancer using nomograms based on MRI tumour regression grade

MRI-based Radiomics to Predict Neoadjuvant Chemoradiotherapy Outcomes in Locally Advanced Rectal Cancer: A Multicenter Study

Radiopathomics Integrated Artificial Intelligence Predict Neoadjuvant Treatment Response for Locally Advanced Rectal Cancer: A Multicentre, Retrospective, Cohort Study

Predicting the Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Using Soluble Immune Checkpoints

Development and validation of a radiomics model based on lymph-node regression grading after neoadjuvant chemoradiotherapy in locally advanced rectal cancer.

Association of Markers of Systemic and Local Inflammation with Prognosis of Patients with Rectal Cancer Who Received Neoadjuvant Radiotherapy

Peripheral Blood Inflammation Indicators as Predictive Factors for Treatment Response Assessed by MRI in Cervical Cancer Patients Referred for Radiotherapy

Biomarkers for Predicting the Response to Radiation-Based Neoadjuvant Therapy in Rectal Cancer

Mri-Based Radiomics Signature for Predicting Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Rectal Cancer: A Multicentre Study